JPRN-UMIN000049225招募中Unknown
Rechallenge of afatinib for EGFR mutated non-small cell lung cancer previously treated with osimertinib - Afatinib followed by osimertinib in patients with EGFR mutated NSCLC (REAL study)
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Having active multiple malignancies 2) Having active infectious disease (hepatitis B, hepatitis C, tuberculosis, HIV infection) 3) Pregnancy, breastfeeding or suspected of being pregnant 4) Undergoing concurrent anticancer therapy (chemotherapy, radiotherapy, immunotherapy, biological therapy, hormonal therapy) 5) Undergoing surgical treatment with organ removal within 28 days prior to registration
研究者
相似试验
进行中（未招募）
不适用
Afatinib translational study in patients with EGFR mutation-positive non-squamous non-small cell lung cancer acquired resistance to osimertinibEGFR mutation-positive non-squamous non-small cell lung cancerJPRN-jRCTs071180013Ryo Toyozawa30
尚未招募
2 期
Effectiveness and feasibility of afatinibe in EGFR mutated non-small cell lung cancer patients with postoperative recurrence. -Phase II studyEGFR mutated non-small cell lung cancer patients with postoperative recurrenceJPRN-UMIN000014443Gunma university38
已完成
2 期
Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancernon-small cell lung cancerJPRN-C000000151West Japan Oncology Group25
已完成
不适用
Phase II study of EGFR-TKI rechallenge with afatinib in advanced NSCLC patients haboring sensitive EGFR mutation without T790MJPRN-UMIN000015568Okayama University Hospital12
Unknown
2 期
A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of EsophagusSquamous Cell Carcinoma of EsophagusNCT02353936Yonsei University30